199103-19-0

Basic information

• Product Name: 1-((BENZYLOXY)CARBONYL)PIPERIDIN-4-YL METHANESULFONATE
• Synonyms: 1-((BENZYLOXY)CARBONYL)PIPERIDIN-4-YL METHANESULFONATE;1-Piperidinecarboxylic acid, 4-[(Methylsulfonyl)oxy]-, phenylMethyl ester;benzyl 4-(methanesulfonyloxy)piperidine-1-carboxylate;Benzyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate;1-Cbz-4-(mesyloxy)piperidine
• CAS NO: 199103-19-0
• Molecular Formula: C₁₄H₁₉NO₅S
• Molecular Weight: 313.36936
• Mol File: 199103-19-0.mol

Chemical Properties

• Boiling Point: 492.3±44.0 °C(Predicted)
• Appearance: /
• Density: 1.31±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -3.07±0.40(Predicted)
• CAS DataBase Reference: 1-((BENZYLOXY)CARBONYL)PIPERIDIN-4-YL METHANESULFONATE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-((BENZYLOXY)CARBONYL)PIPERIDIN-4-YL METHANESULFONATE(199103-19-0)
• EPA Substance Registry System: 1-((BENZYLOXY)CARBONYL)PIPERIDIN-4-YL METHANESULFONATE(199103-19-0)

Safety Data

• Hazardous Substances Data: 199103-19-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-((Benzyloxy)carbonyl)piperidin-4-yl methanesulfonate is used as an intermediate for the preparation of conformationally restricted saturated nitrogen heterocyclic sulfonyl chloride. This application is significant because it allows for the development of new pharmaceutical compounds with specific structural features that can potentially enhance their therapeutic properties, such as improved binding affinity, selectivity, and bioavailability.
Used in Chemical Synthesis:
In the field of chemical synthesis, 1-((Benzyloxy)carbonyl)piperidin-4-yl methanesulfonate serves as a valuable building block for the creation of more complex molecules. Its unique structure can be further modified and functionalized to produce a wide range of chemical products, including specialty chemicals, agrochemicals, and advanced materials.
Used in Research and Development:
Due to its unique chemical properties and potential applications, 1-((Benzyloxy)carbonyl)piperidin-4-yl methanesulfonate is also utilized in research and development laboratories. Scientists and researchers can use 1-((BENZYLOXY)CARBONYL)PIPERIDIN-4-YL METHANESULFONATE to explore new reaction pathways, develop innovative synthetic methods, and investigate its potential interactions with various biological targets.

Upstream product

• 95798-23-5 1-(benzyloxycarbonyl)-4-hydroxypiperidine 
• 7143-01-3 Methanesulfonic anhydride 
• 501-53-1 benzyl chloroformate 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 161609-84-3 4-cyanopiperidine-1-carboxylic acid benzyl ester 
• 1104449-35-5 benzyl 4-(2-oxo-1,2-dihydropyridin-4-yloxy)piperidine-1-carboxylate 
• 287953-54-2 4-(chlorosulfonyl)piperidine-1-carboxylic acid benzyl ester 
• 66207-23-6 1-benzyloxycarbonyl-1,2,3,6-tetrahydropyridine 
• 146827-60-3 4-(acetylthio)-1-(benzyloxycarbonyl)piperidine 

Relevant articles and documents

BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF

Provided is a novel class of orally and/or topically available, selective and potent JAK inhibitors as safe and effective therapeutics against various diseases and disorders. Also provided is pharmaceutical composition of these compounds and methods of th

BENZAMIDES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF

Provided is a novel class of orally and/or topically available, selective and potent JAK inhibitors as safe and effective therapeutics against various diseases and disorders. More particularly, provided are pharmaceutical composition of these compounds and methods of their preparation and use thereof.

NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS

The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R1 may optionally be substituted; and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE

In its many embodiments, the present invention provides certain substituted bispiperidinyl compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein ring A, ring B, R1, R2, R3, L, R4, X, Z, Li, Q and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver Χ-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES

Provided herein are methods for treating, preventing, or ameliorating one or more symptoms of a condition, disorder, or disease mediated by a lipid kinase or a protein kinase with benzimidazoles, for example, of Formula I or II, and pharmaceutical compositions thereof. Also provided herein are benzimidazoles, and pharmaceutical compositions thereof; and methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.

BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER

Provided herein are benzimidazole derivatives, for example, of Formula I, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.

Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1 H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119

G-protein-coupled receptor 119 (GPR119) is expressed predominantly in pancreatic β-cells and in enteroendocrine cells in the gastrointestinal tract. GPR119 agonists have been shown to stimulate glucose-dependent insulin release by direct action in the pancreas and to promote secretion of the incretin GLP-1 by action in the gastrointestinal tract. This dual mechanism of action has generated significant interest in the discovery of small molecule GPR119 agonists as a potential new treatment for type 2 diabetes. Herein, we describe the discovery and optimization of a new class of pyridone containing GPR119 agonists. The potent and selective BMS-903452 (42) was efficacious in both acute and chronic in vivo rodent models of diabetes. Dosing of 42 in a single ascending dose study in normal healthy humans showed a dose dependent increase in exposure and a trend toward increased total GLP-1 plasma levels.

A library of conformationally restricted saturated heterocyclic sulfonyl chlorides

An approach to the synthesis of conformationally restricted saturated heterocyclic sulfonyl chlorides is described. Being guided by the principle of diversity-oriented conformational restriction, a mini-library of saturated heterocyclic sulfonyl chlorides

6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS

The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, their synthesis, and their use as CHK-1 inhibitors.

PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS

Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR 119 G protein-coupled receptor modulator therapy. These novel compounds have the structure Formula I or Formula IA.